Silo Pharma (SILO) Receivables - Other (2020 - 2024)

Silo Pharma (SILO) posted Receivables - Other of $9600.0 for Q2 2024, little changed sequentially from $9600.0 in Q1 2024.

Silo Pharma (SILO) Receivables - Other (2020 - 2024) Analysis & Trends

Silo Pharma has reported Receivables - Other for 5 years, with the latest figure at $9600.0 in Q2 2024.

Quarterly Receivables - Other changed N/A year-over-year to $9600.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $9600.0 (changed N/A YoY) and the FY2023 annual result came in at $9600.0, up 59.73% from the prior year.
Receivables - Other held at $9600.0 in Q2 2024 per SILO's latest filing, from $9600.0 in the prior quarter.
Over five years, Receivables - Other peaked at $60000.0 in Q4 2021 and troughed at $6010.0 in Q4 2022.
A 5-year average of $33145.6 and a median of $23500.0 in 2020 frame the typical range for Receivables - Other.
The sharpest annual moves came in 2021 and 2022: Receivables - Other jumped 155.32% in 2021, then sank 89.98% in 2022.
Over 5 years, Receivables - Other stood at $23500.0 in 2020, then soared by 155.32% to $60000.0 in 2021, then tumbled by 89.98% to $6010.0 in 2022, then jumped by 59.73% to $9600.0 in 2023, then changed by 0.0% to $9600.0 in 2024.
According to Business Quant data, Receivables - Other over the past three periods registered $9600.0, $9600.0, and $9600.0 for Q2 2024, Q1 2024, and Q3 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	140.22 Bn	132.37 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.29 Bn	78.30 Bn	3.93 Bn
3	Argenx Se	65.17 Bn	59.98 Bn	1.37 Bn
4	Moderna	61.38 Bn	56.24 Bn	52.00 Mn
5	BeOne Medicines	42.18 Bn	37.09 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.99 Bn	27.68 Bn	992.69 Mn
7	BioNTech SE	28.45 Bn	10.05 Bn	668.28 Mn
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Silo Pharma	3.01 Mn	3.01 Mn	-

Download Data